A US based emerging biopharma recognized that one of their anti-viral therapeutics being developed for a different indication might also help in the fight against the Coronavirus, COVID-19. Due to the emergency of the global pandemic they knew they had to react fast to meet the challenge but didn’t have the internal resources available.
Resources
blog
Embarking on the journey to expand into the United States market is a pivotal moment for any European biotech company.…
blog
Phages, also known as Bacteriophages, are viruses that infect specific bacteria and provoke their death via lytic activity. They are…
blog
2024 is here and will be a crucial year for your clinical trials in the European Union (EU) and European…
blog
In our previous posts, we explored software tools used in digital health and set the foundations around potential applications of…
